RAPID ENROLLMENT FOR FASTER REAL-WORLD EVIDENCE

Answer the questions that matter most in drug evidence

Stop waiting on sites or settling for shallow data — generate decision-grade evidence on your timeline. PicnicHealth's evidence platform enrolls faster and captures the complete treatment story, using a direct-to-patient approach and strategic recruitment channels to deliver the right patients at the right time.

Vertical sidebar with seven circular icons representing data analysis, layered stacks, test tube with checkmark, smartwatch, pills, person with directional arrows, checklist, and a house with a medical cross and checkmark.

Decision-grade drug evidence

Access a strategic evidence asset that adapts as your research needs evolve.

Long-term real-world safety and effectiveness

Treatment patterns, drug utilization, and adherence

Treatment burden and tolerability

Discontinuation drivers and reasons for switching

Patient experience and quality of life

Post-marketing requirements and commitments

The strategic solution for real-world drug evidence

30-50%

more cost-effective than site-based models

75%

of drug studies enroll on time or faster than enrollment forecast

Line graph showing actual enrollment steadily rising from 0 to about 450, below the target enrollment line set at 500.

Patient-Mediated Drug Evidence

What makes our approach different?

Map with medical visit locations for Patient X, a 35-year-old male, showing emergency room visits, primary care, neurologist, cardiologist, and pharmacy points.

Rapid enrollment, rapid insights

We strategically target the patients you’re looking for. By enrolling patients through specialty pharmacies (SP) and manufacturer-sponsored patient support programs (PSP), we reach patients at or near therapy initiation, in addition to multichannel digital outreach and patient community partnerships. This enrollment strategy accelerates time from study initiation to insight.

Research informed by complete patient journeys

Our direct-to-patient approach and AI-powered technology enables us to access complete retrospective patient histories and capture ongoing prospective data. Through our patient app, patients can also contribute additional patient-generated data through PROs, surveys, and wearables, and access tools that help them in their own care journey.

Learn about the patient app

Diagram showing a sequence from a woman submitting a document to AI processing involving text and brain image analysis, leading to refined outputs.

Abstract design with overlapping thin teal and gray lines forming circular and wave-like patterns on a light background.

Designed for precision & flexibility

Every element of your study design, protocol, and CRF is tailored to your specific endpoints and research objectives. And as your program grows, our flexible data model accommodates emerging research questions without costs amendment or structural redesign. The results it an evidence asset that evolves with your program’s needs.

End-to-end visibility

Make more informed decisions with real-time, insight-ready visuals delivered through our sponsor portal. Track enrollment progress, participant representation, and survey responses — then at data delivery, receive enhanced visualizations across all variables relevant to your study objectives.

Learn more about the sponsor portal

Study overview dashboard showing total patients enrolled as 195 out of 300, divided into 96 in Group A and 99 in Group B, with enrollment progress and site enrollment bar charts, and demographic charts of sex assigned at birth (100% female) and age at enrollment for Groups A and B.

Learn more

Explore our drug evidence resources

Man with glasses talking to a healthcare professional, with text about Specialty Pharmacy and PicnicHealth partnership to improve rare disease patient care, and logos of PicnicHealth and Orsini.

PicnicHealth overview document titled 'Decision-Grade Drug Evidence' outlining a platform that delivers comprehensive drug evidence for researchers, highlighting key benefits such as 72% on-time study enrollment and 98% patient retention.